Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Alprazolam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 7/20 | 1.00 |
| ▸ | GABRA5 known ✓ | P31644 | 7/20 | 1.00 |
| ▸ | GABRA2 known ✓ | P47869 | 7/20 | 1.00 |
| ▸ | GABRB2 known ✓ | P47870 | 6/20 | 1.00 |
| ▸ | GABRA3 known ✓ | P34903 | 5/20 | 1.00 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 0.77 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 0.77 |
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.58 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.58 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.58 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.58 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.58 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.58 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.58 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 0.58 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 5/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | BRD4 | O60885 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alprazolam SCHEMBL29381667 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRB2OPRK1 | |
| Alprazolam SCHEMBL16922178 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRB2OPRK1 | |
| Alprazolam SCHEMBL5480614 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRB2OPRK1 | |
| Alprazolam SCHEMBL22527891 | 0.99 | GABRA1 (0.98) | GABRA1GABRA5GABRA2GABRB2OPRK1 | |
| Alprazolam SCHEMBL28964138 | 0.99 | GABRA1 (0.98) | GABRA1GABRA5GABRA2GABRB2OPRK1 | |
| Alprazolam SCHEMBL2420072 | 0.91 | GABRA1 (0.82) | GABRA1GABRA5GABRA2GABRB2OPRK1 | |
| Alprazolam SCHEMBL4973049 | 0.91 | GABRA1 (0.82) | GABRA1GABRA5GABRA2GABRB2OPRK1 | |
| SCHEMBL7323630 | 0.89 | OPRK1 (0.80) | GABRA1GABRA5GABRA2GABRB2OPRK1 | |
| SCHEMBL11825281 | 0.88 | OPRK1 (0.78) | GABRA1GABRA5GABRA2GABRB2OPRK1 | |
| Triazolam SCHEMBL29228 | 0.87 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRB2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 134241 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122075410-A | Dry powder composition for intranasal delivery | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026106495-A1 | DISMANTLABLE PROTECTIVE ROLL CAGE FOR VEHICLES | PAYE AQUISE LENIN ABAD (PE) | 2026-05-21 | — | — | WO | claimed |
| CN-122065592-A | Hydrogen permeation numerical simulation method for defect-containing pipeline affected by sulfate reducing bacteria corrosion | 福州大学 | 2026-05-19 | — | — | CN | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| CN-122035832-A | Preparation method of graphite nitrogen-pyridine nitrogen co-doped two-dimensional carbon nanomaterial and method for electrochemically screening electron-rich aromatic pollutants | 南开大学 | 2026-05-15 | — | — | CN | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| CN-122016625-A | Variable ammonia alcohol hydrogen environment multi-type corrosion testing device and testing method | 福州大学 | 2026-05-12 | — | — | CN | claimed |
| US-20260115161-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | LAMINAR PHARMACEUTICALS S A (ES) | 2026-04-30 | — | — | US | claimed |
| EP-0018366-A4 | METHOD AND APPARATUS FOR EFFECTING SUBSURFACE, CONTROLLED, ACCELERATED CHEMICAL REACTIONS. | MCGREW JAY LININGER | 1980-06-23 | — | — | EP | claimed |
| EP-0007907-A1 | AUDIBLE VOLTAGE-IMPEDANCE TESTER | BERENDONK, Bengt (US) | 1980-02-06 | — | — | EP | claimed |
| EP-0006940-A1 | THE PRODUCTION OF ELECTROLYTIC MANGANESE DIOXIDE | Diamond Shamrock Technologies S.A. (CH) | 1980-01-23 | — | — | EP | claimed |
| WO-1979000791-A1 | METHOD AND APPARATUS FOR EFFECTING SUBSURFACE,CONTROLLED,ACCELERATED CHEMICAL REACTIONS | MCGREW J | 1979-10-18 | — | — | WO | claimed |
| WO-1979000389-A1 | AUDIBLE VOLTAGE-IMPEDANCE TESTER | BERENDONK B (US) | 1979-07-12 | — | — | WO | claimed |
| WO-1979000258-A1 | THE PRODUCTION OF ELECTROLYTIC MANGANESE DIOXIDE | DIAMOND SHAMROCK TECHN (CH) | 1979-05-17 | — | — | WO | claimed |
| US-4075221-A | ALKYLATION WITH DIALKYLMETHYLENEAMMONIUM SALT IN PRESENCE OF REACTIVE CARBOXYLIC ACYLATING AGENT | THE UPJOHN COMPANY (US) | 1978-02-21 | — | — | US | claimed |
| US-3994941-A | METHYLOLATION, PHTHALIMIDATION | THE UPJOHN COMPANY (US) | 1976-11-30 | — | — | US | claimed |
| US-3987052-A | SEDATIVES, TRANQUILIZERS, MUSCLE RELAXANTS | THE UPJOHN COMPANY (US) | 1976-10-19 | — | — | US | claimed |
| US-3980789-A | SOPORIFICS AND SLEEP INDUCERS | THE UPJOHN COMPANY (US) | 1976-09-14 | — | — | US | claimed |